MMRGlobal (MMRF) Inactive 10-Q23 May 162016 Q1 Quarterly reportFinancial data

Company Profile

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
Document and Entity Information - shares	Mar. 31, 2016	May. 11, 2016
Document And Entity Information
Entity Registrant Name	MMRGlobal, Inc.
Entity Central Index Key	1,285,701
Document Type	10-Q
Document Period End Date	Mar. 31, 2016
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Smaller Reporting Company
Entity Common Stock, Shares Outstanding		233,073,991
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2,016

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Cash and cash equivalents	$ 0	$ 0
Accounts receivable, less allowances of $215,483 in 2016 and 2015	11,744	27,934
Inventory	0	0
Prepaid expenses and other current assets	131,250	0
Total current assets	142,994	27,934
Property and equipment, net	15,495	19,071
Intangible assets, net	669,603	669,603
Total assets	828,092	716,608
Current liabilities:
Line of credit, related party	1,360,682	1,002,428
Related party payables	1,575,881	1,385,901
Compensation payable	732,210	727,509
Severance liability	620,613	620,613
Accounts payable and accrued expenses	4,311,270	4,420,585
Convertible notes payable	323,749	323,749
Notes payable, current portion	369,413	369,413
Notes payable, related party	56,743	56,743
Capital leases payable, current portion	13,221	13,221
Total current liabilities	$ 9,363,782	$ 8,920,162
Commitments and contingencies (See Note 9)
Stockholders' deficit:
Preferred stock - $0.001 per value, 5,000,000 shares authorized, 0 issued and outstanding.
Common stock, $0.001 par value, 1,250,000,000 shares authorized, 221,593,227 and 211,851,177 shares issued and outstanding as of March 31, 2016 and December 31, 2015, respectively	$ 1,068,792	$ 1,059,050
Additional paid-in capital	57,829,245	57,687,270
Accumulated deficit	(67,433,727)	(66,949,874)
Total stockholders' deficit	(8,535,690)	(8,203,554)
Total liabilities and stockholders' deficit	$ 828,092	$ 716,608

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Current assets:
Allowances	$ 215,483	$ 215,483
Stockholders' deficit:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	1,250,000,000	1,250,000,000
Common stock, shares issued	221,593,227	211,851,177
Common stock, shares outstanding	221,593,227	211,851,177

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended
Condensed Consolidated Statements of Operations - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Income Statement [Abstract]
Revenues	$ 16,488	$ 44,701
Cost of revenues	19,937	73,332
Gross profit	(3,449)	(28,631)
General and administrative expenses	376,199	461,992
Sales and marketing expenses	52,335	157,451
Loss from operations	(431,983)	(648,074)
Other income	0	0
Interest and other finance charges, net	(51,870)	(93,269)
Net loss	$ (483,853)	$ (741,343)
Net (loss) income per share:
Basic and diluted	$ 0	$ 0
Weighted average common shares outstanding:
Basic	214,871,808	155,273,892
Diluted	214,871,808	155,273,892

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
Condensed Consolidated Statements of Cash Flows - USD ($)	Mar. 31, 2016	Mar. 31, 2015
Operating activities:
Net loss	$ (483,853)	$ (741,343)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	3,576	94,101
Warrants issued for services	0	5,490
Stock-based compensation	5,586	5,525
Common stock issued for services	0	13,000
Amortization of loan discount	0	55,780
Subtotal - non-cash adjustments	9,162	173,896
Effect of changes in:
Accounts receivable	16,190	(1,296)
Prepaid expenses and other current assets	0	1,450
Accounts payable and accrued expenses	(94,434)	220,584
Related party payables	189,980	60,136
Compensation payable	4,701	48,350
Deferred revenue	0	(4,192)
Subtotal - net change in operating assets and liabilities	116,437	325,032
Net cash used in operating activities	(358,254)	(242,415)
Investing activities:
Purchase of property and equipment	0	(1,253)
Filing of patents	0	(97,700)
Net cash used in investing activities	0	(98,953)
Financing activities:
Book overdraft	0	20,779
Proceeds on line of credit	358,254	11,196
Net cash provided by financing activities	358,254	31,975
Net decrease in cash	0	(309,393)
Cash, beginning of period	0	309,393
Cash, end of period	0	0
Supplemental disclosures of cash flow information:
Interest paid in cash	0	93,268
Income taxes paid in cash	0	1,675
Supplemental disclosure of non-cash investing and financing activities:
Shares issued for reduction of payables	$ 146,131	$ 18,000

NATURE OF OPERATIONS AND BASIS

NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1	3 Months Ended
NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1	Mar. 31, 2016
Notes to Financial Statements
NATURE OF OPERATIONS AND BASIS OF PRESENTATION - Note 1	NOTE 1 - NATURE OF OPERATIONS AND BASIS OF PRESENTATION MMRGlobal Inc. (referred to herein, unless otherwise indicated, as "MMR," the "Company," the "issuer," "we," "us," and "our") was originally incorporated as Favrille, Inc. ("Favrille") in Delaware in 2000, and since its inception and before the Merger (as defined below), operated as a biopharmaceutical company focused on the development and commercialization of targeted immunotherapies for the treatment of cancer and other diseases of the immune system. In May 2008, Favrille's ongoing Phase 3 registration trial for the FavId vaccine failed to show a statistically significant improvement in the treatment of patients with follicular B-cell Non-Hodgkin's lymphoma. On January 27, 2009, the Company, through MyMedicalRecords, Inc. ("MMR Inc."), what is now our wholly-owned operating subsidiary, conducted a reverse merger with Favrille. Through our wholly-owned operating subsidiary MMR Inc., the Company's primary business is to license and provide secure and easy-to-use online Personal Health Records ("PHR") and MyEsafeDepositBox storage solutions, including a professional offering to physicians' offices and similar organizations known as MMRPro. In January 2009, as a result of the Merger, we acquired biotech assets and other intellectual property including anti-CD20 antibodies as well as data and samples from the FavId/Specifid vaccine clinical trials for the treatment of B-cell Non-Hodgkin's lymphoma. On March 8, 2011, we formed a subsidiary, which we named MMR Life Sciences Group, Inc., exclusively to maximize the value of our biotech assets including our patents, anti-CD 20 antibodies, and FavId vaccine technologies acquired by MyMedicalRecords, Inc. through the merger with Favrille. As of this date the assets have not been transferred to the subsidiary. We (formerly Favrille) were incorporated in Delaware in 2000, MMR Inc. was incorporated in Delaware in 2005, and both are headquartered in Los Angeles, CA. Principles of Consolidation The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation. Basis of Presentation We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended March 31, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015. Going Concern and Management's Plan As of March 31, 2016, our current liabilities exceeded our current assets by $9.2 million. Furthermore, during the three months ended March 31, 2016, we incurred losses of $483,853, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q. At March 31, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Tenth Amended and Restated Note effective May 20, 2015 (the "Line of Credit"), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,362,633 at March 31, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $2,612,633, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Tenth Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of March 31, 2016 are as follows: $1,360,682, which is included in the line of credit, related party; and $1,001,950 related to other obligations due to The RHL Group which are included in related party payables. Management's plan regarding this matter is to, amongst other things, continue to utilize our available line of credit with The RHL Group (see Note 3). As of March 31, 2016, we had approximately $1,887,367 remaining as available under The RHL Group line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue licensing our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available line of credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2	3 Months Ended
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2	Mar. 31, 2016
Notes to Financial Statements
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Note 2	NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) MANAGEMENT'S USE OF ESTIMATES The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates. (b) CASH AND CASH EQUIVALENTS We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of March 31, 2016 and December 31, 2015, respectively. (c) TRADE AND OTHER RECEIVABLES Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due. (d) FAIR VALUE OF FINANCIAL INSTRUMENTS ASC 820-10, Fair Value Measurements and Disclosures, We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements. Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1: Quoted prices in active markets for identical or similar assets and liabilities. Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. (e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the three months ended March 31, 2016 and 2015. (f) REVENUE RECOGNITION We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable. Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met. We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under "License Fees." In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 - Revenue Recognition - Multiple-Element Arrangements We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, Revenue Recognition, Multiple-Element Arrangements Our multiple-deliverable arrangements consist solely of our MMRPro product. Significant deliverables within these arrangements include sophisticated scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties. We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We provide other software licenses, telephone lines and online secure storage over the three year term of the agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable. We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis. We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin ("SAB") No. 104, Topic 13: Revenue Recognition Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, Revenue Recognition Milestone Method. (g) SHARE-BASED COMPENSATION We account for share-based compensation in accordance with ASC 718-20, Awards Classified as Equity We account for options and warrants issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the three months ended March 31, 2016. We valued grants of stock options and warrants during the three months ended March 31, 2015 using the following assumptions. Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0% We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees. (h) NET INCOME/LOSS PER SHARE We apply the guidance of ASC 260-10, Earnings Per Share We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the three months ended March 31, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 20,272,887 shares for the three months ended March 31, 2016 and 29,791,116 shares for the three months ended March 31, 2015, respectively. (i) RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606) (j) RECLASSIFICATIONS Certain numbers in the prior year have been reclassified to conform to the current year's presentation.

RELATED PARTY PAYABLES, LINE OF

RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3	3 Months Ended
	Mar. 31, 2016
Notes to Financial Statements
RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE - Note 3	NOTE 3 - RELATED PARTY PAYABLES, LINE OF CREDIT AND NOTE PAYABLE On May 20, 2015, we and The RHL Group entered into a Tenth Amended and Restated Promissory Note (the " Amended Note Existing Note Credit Facility Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the "Security Agreement"). The Tenth Amended Note had a current balance of $2,362,633 at March 31, 2016. The components of the Tenth Amended Note and the related balance sheet presentation as of March 31, 2016 are as follows: $1,360,682, which is included in the line of credit, related party; and $1,001,951 for other obligations due to The RHL Group, which is included in related party payables. Total interest expense on the Line of Credit for the three months ended March 31, 2016 and 2015 amounted to $68,973 and $30,676, respectively. The unpaid interest balances as of March 31, 2016 and December 31, 2015 were $189,739 and $60,257, respectively. In conjunction with the Tenth Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes on and after March 31, 2016. Since we did not meet these covenants as of March 31, 2016, we received a second waiver from The RHL Group until June 1, 2016.

INCOME TAXES - Note 4

INCOME TAXES - Note 4	3 Months Ended
INCOME TAXES - Note 4	Mar. 31, 2016
Notes to Financial Statements
INCOME TAXES - Note 4	NOTE 4 - INCOME TAXES Under ASC 740-270, Income Taxes - Interim Reporting Pursuant to ASC 740, Income MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the three months ended March 31, 2016. We account for income taxes in accordance with ASC 740-10, Income Taxes

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Note 5	3 Months Ended
COMMITMENTS AND CONTINGENCIES - Note 5	Mar. 31, 2016
Notes to Financial Statements
COMMITMENTS AND CONTINGENCIES - Note 5	NOTE 5 - COMMITMENTS AND CONTINGENCIES Leases Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250. Total rent expense for the three months ended March 31, 2016 and 2015 were $26,445 and $30,670 respectively. Future minimum lease payments as of March 31, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows: Year Ending Operating Capital December 31, Leases Leases 2016 (Remainder of) $ 142,175 $ 13,222 2017 206,305 - 2018 146,410 - Total minimum lease payments $ 494,890 $ 13,222
Legal Matters and Contingencies - Note 5	Litigation Matters From time to time, we are involved in various legal proceedings generally incidental to our business. While the result of any litigation contains an element of uncertainty, our management presently believes that the outcome of any known, pending or threatened legal proceeding or claim, individually or combined, will not have a material adverse effect on our financial statements. On December 9, 2011, MyMedicalRecords, Inc. entered into a Non-Exclusive Settlement and Patent License Agreement with Surgery Center Management LLC ("SCM"). In consideration for the rights granted under that Agreement and in consideration of a settlement and release agreement, SCM contracted to pay MyMedicalRecords, Inc. an initial payment of $5 million payable on December 23, 2011, and additional payments of $5 million per year for five consecutive years. After unsuccessful attempts to collect the past due amount of $5 million, on January 19, 2012, MyMedicalRecords, Inc. filed a lawsuit in the Superior Court of the State of California for the County of Los Angeles for breach of contract. At this time, MMR believes that SCM owes the Company $30 million plus interest, and on August 4, 2015, the Court granted MMR leave to amend its complaint to seek damages of $30 million (plus interest) from SCM since the end of 2011, and SCM filed an answer to MMR's amended complaint. On February 13, 2014, SCM filed a cross-complaint alleging claims for breach of that contract, among other things. On July 10, 2014, the court granted SCM's motion for summary adjudication on the claim for breach of contract in the complaint and its counterclaim for declaratory relief. On July 30, 2014, SCM filed its second amended cross-complaint, alleging substantially the same claims against the same parties. On December 5, 2014, the Court of Appeal issued an Alternative Writ of Mandate, finding the trial court erred in granting SCM's motion for summary adjudication. Pursuant to the Court of Appeal's Alternative Writ, on January 7, 2015, the trial court vacated its order granting SCM's motion for summary adjudication. On April 24, 2015, the trial court held a new hearing on that motion, and it entered an order denying SCM's motion in its entirety. The case is scheduled for trial on November 1, 2016. MyMedicalRecords, Inc. will continue to pursue its claim and defenses, but the Company cannot predict the chances of either a favorable or unfavorable outcome, nor does the Company have sufficient information regarding its ability to collect any judgment MyMedicalRecords, Inc. may obtain. On April 2, 2015, the Company and Stradling Yocca Carlson & Rauth, P.C. ("SYCR"), were notified of the determination of an arbitrator in regards to disputes over amounts of monies due SYCR regarding prior services rendered. SYCR and the Company has previously agreed to a non-binding arbitration of the matter. The Company received an award in favor of SYCR in the amount of $285,000 which the Company disputes, notwithstanding, that it represents a reduction of SYCR's original $571,000 claim or $286,000 in favor of the Company. Since the arbitration award is non-binding the Company has filed an appeal of the remaining award. The Company cannot predict the chances of either a favorable or unfavorable outcome of the appeal. Two separate MyMedicalRecords health IT patents were accepted by the Australia Patent Office in 2015 and are currently under Opposition. On January 8, 2015, Australia Patent Application No. 2011307287, "Universal Patient Record Conversion Tool," was accepted by the Australia Patent Office. An opposition was filed on April 21, 2015 by the Crown in the Right of the Commonwealth of Australia (Department of Health). A second opposition was filed on April 22, 2015 by the Medical Software Industry Association, Inc. which aligned itself with the Crown. Evidence has been submitted by the parties and a hearing is being scheduled in 2016. In the interim, a divisional application, Australia Patent Application No.2015201900, was filed on October 15, 2015. Elsewhere, Patent No. 326616 with the same title and subject matter was issued in Mexico on January 6, 2015, and on May 5, 2016, we received notice that the "Universal Patient Record Conversion Tool," Patent Application No. 2013023072, was accepted and is being granted in Singapore. On July 6, 2015, Australia Patent Application No. 2013212253, "Mobile Platform for Personal Health Records," was accepted by the Australia Patent Office. An opposition was filed on October 13, 2015 by the Medical Software Industry Association, Inc. and a second opposition was filed on October 16, 2015, by the Crown in the Right of the Commonwealth of Australia (Department of Health). A third opposition was filed on October 16, 2015, by the National E-Health Transition Authority Limited (NEHTA). The first opposition was dismissed on February 19, 2016. The second opposition and the third opposition remain pending. MMR's Evidence in Answer is due to be filed by July 19, 2016 in Australia. In the interim, a divisional application, Australia Patent Application No. 2015243029, was filed on October 15, 2015 and is pending. An additional divisional application under "Mobile Platform for Personal Health Records," Australia Patent Application No. 2015101556, was filed on October 21, 2015 and granted on November 12, 2015 as an Innovation Patent. In addition to Australia Patent No. 2015101556, MMR was previously issued two Australia health IT patents under the title "Method and System for Providing Online Medical Records": Patent No. 2006202057 issued on May 29, 2008 and Patent No. 2008202401 issued on December 24, 2009.

STOCKHOLDERS' DEFICIT - Note 6

STOCKHOLDERS' DEFICIT - Note 6	3 Months Ended
STOCKHOLDERS' DEFICIT - Note 6	Mar. 31, 2016
Notes to Financial Statements
STOCKHOLDERS' DEFICIT - Note 6	NOTE 6 - STOCKHOLDERS' DEFICIT Preferred Stock We have 5,000,000 shares of preferred stock authorized. As of March 31, 2016, and December 31, 2015, there were no shares of preferred stock issued and outstanding. Common Stock As of March 31, 2016, we are authorized to issue 1,250,000,000 shares of common stock. On February 2, 2016, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Certificate of Amendment") with the Secretary of State of the State of Delaware effecting a five for one reverse stock split of the Company's common stock (the "Reverse Stock Split") which became effective in the marketplace on February 8, 2016. The number of shares and per share amounts have been retroactively restated to reflect this reverse stock split. As of March 31, 2016, the total shares of our common stock issued and outstanding amounted to 221,593,227.

EQUITY ISSUANCES - Note 7

EQUITY ISSUANCES - Note 7	3 Months Ended
EQUITY ISSUANCES - Note 7	Mar. 31, 2016
Notes to Financial Statements
EQUITY ISSUANCES - Note 7	0.75 326,053 2.39 $ 0.90 326,053 2.39 $ 0.90 7,488,345 7,348,345 Warrants During the three months ended March 31, 2016, there were no warrants issued A summary of the activity of our warrants for the three months ended March 31, 2016 is presented below: Weighted Avg Shares Exercise Price Outstanding at December 31, 2015 11,428,610 $ 0.30 Granted - - Exercised - - Cancelled (850,000) 0.56 Outstanding at March 31, 2016 (Unaudited) 10,578,610 $ 0.28 Exercisable at March 31, 2016 (Unaudited) 10,511,944 $ 0.28 Total warrant expenses recorded during the three months ended March 31, 2016 and 2015 were $2,352 and $5,490, respectively. The following summarizes the total warrants outstanding and exercisable as of March 31, 2016: Warrants Outstanding Warrants Exercisable Warrants Weighted Avg Weighted Avg Warrants Weighted Avg Weighted Avg Ranges Outstanding Remaining Life Exercise Price Exercisable Remaining Life Exercise Price $0.02 - $0.30 8,182,798 1.42 $ 0.20 8,116,131 1.41 $ 0.20 $0.30 - $0.50 255,000 1.03 0.50 255,000 1.03 0.50 Greater $0.50 2,140,812 0.55 0.75 2,140,812 0.55 0.75 10,578,610 10,511,944 The inputs used for the Black-Scholes option and warrant valuation model were as follows: Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0% Shares Issued for Services or Reduction to Liabilities During the three months ended March 31, 2016, we issued 9,742,050 shares of common stock with a value of $146,131 to various third parties and charged the proceeds to the appropriate accounts for the following reasons: Three Months Ended March 31, 2016 Purpose Shares Value Services provided - $ - Reduction of payables 9,742,050 146,131 Totals 9,742,050 $ 146,131 The 9,742,050 issued shares were not contractually restricted. However, as these shares have not been registered under the Securities Act of 1933, as amended (the "Act"), they are restricted from sale until they are registered under the Act, or qualify for resale under the rules promulgated under the Act. All such shares were calculated at the trading closing price on the date of issuance. Stock Bonus Agreements From time to time, we issue shares of our common stock as a bonus for services rendered. Stock bonuses may be awarded upon satisfaction of specified performance goals pursuant to the Performance Stock Bonus Agreement. On each grant date, we valued the stock bonus based on the share price and the expenses were amortized using the straight line method. Total stock bonus expenses recorded during the three months ended March 31, 2016 and 2015 were $0 and $0, respectively and are reflected in operating expenses in the accompanying consolidated statements of operations. " id="sjs-B4" xml:space="preserve">NOTE 7 - EQUITY ISSUANCES Stock Option Activity Our 2001 Equity Incentive Plan (the "2001 Plan") expired on June 5, 2011 and no options were issued under the 2001 Plan since that date. As of March 31, 2016, 2,836,911 shares remain issued under the 2001 Plan. On September 1, 2011, our Board of Directors approved the adoption of a new plan to replace the 2001 Plan under the same general terms as the 2001 Plan. On June 20, 2012, our stockholders voted and approved the 2011 Equity Incentive Plan (the " 2011 Plan") at our 2012 Annual Stockholder Meeting. As of March 31, 2016, 4.67 million shares remain issued under the 2011 Plan, and 7.29 million shares of our common stock are reserved for future issuance under our 2011 Plan, which includes an automatic 1 million share annual increase pursuant to the terms of the 2011 Plan and a 5 million share increase authorized during our 2013 Annual Stockholder's Meeting. A summary of option activity for the three months ended March 31, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares. Weighted-Average Weighted- Remaining Average Contractual Aggregate Exercise Life Intrinsic Options Price (Years) Value Outstanding at December 31, 2015 7,488,345 $ 0.50 3.62 $ - Granted - - Exercised - - Cancelled - $ - Outstanding at March 31, 2016 (Unaudited) 7,488,345 $ 0.50 3.38 $ - Vested and expected to vest at March 31, 2016 (Unaudited) 7,488,345 $ 0.50 3.38 $ - Exercisable at March 31, 2016 (Unaudited) 7,348,345 $ 0.50 3.34 $ - The aggregate intrinsic value in the table above is before applicable income taxes and is calculated based on the difference between the exercise price of the options and the quoted price of the common stock as of the reporting date. There were no options issued during the three months ended March 31, 2016. Total stock option expenses recorded during the three months ended March 31, 2016 and 2015 were $5,586 and $5,525, respectively, and is reflected in operating expenses in the accompanying consolidated statements of operations. The following table summarizes information about stock options outstanding and exercisable at March 31, 2016. Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Number Remaining Exercise Price of Shares Life (Years) Price of Shares Life (Years) Price $ 0.25 - 0.45 2,560,000 5.56 $ 0.35 2,420,000 5.57 $ 0.30 $ 0.50 - 0.75 4,602,292 2.19 $ 0.55 4,602,292 2.19 $ 0.55 $ > 0.75 326,053 2.39 $ 0.90 326,053 2.39 $ 0.90 7,488,345 7,348,345 Warrants During the three months ended March 31, 2016, there were no warrants issued A summary of the activity of our warrants for the three months ended March 31, 2016 is presented below: Weighted Avg Shares Exercise Price Outstanding at December 31, 2015 11,428,610 $ 0.30 Granted - - Exercised - - Cancelled (850,000) 0.56 Outstanding at March 31, 2016 (Unaudited) 10,578,610 $ 0.28 Exercisable at March 31, 2016 (Unaudited) 10,511,944 $ 0.28 Total warrant expenses recorded during the three months ended March 31, 2016 and 2015 were $2,352 and $5,490, respectively. The following summarizes the total warrants outstanding and exercisable as of March 31, 2016: Warrants Outstanding Warrants Exercisable Warrants Weighted Avg Weighted Avg Warrants Weighted Avg Weighted Avg Ranges Outstanding Remaining Life Exercise Price Exercisable Remaining Life Exercise Price $0.02 - $0.30 8,182,798 1.42 $ 0.20 8,116,131 1.41 $ 0.20 $0.30 - $0.50 255,000 1.03 0.50 255,000 1.03 0.50 Greater $0.50 2,140,812 0.55 0.75 2,140,812 0.55 0.75 10,578,610 10,511,944 The inputs used for the Black-Scholes option and warrant valuation model were as follows: Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0% Shares Issued for Services or Reduction to Liabilities During the three months ended March 31, 2016, we issued 9,742,050 shares of common stock with a value of $146,131 to various third parties and charged the proceeds to the appropriate accounts for the following reasons: Three Months Ended March 31, 2016 Purpose Shares Value Services provided - $ - Reduction of payables 9,742,050 146,131 Totals 9,742,050 $ 146,131 The 9,742,050 issued shares were not contractually restricted. However, as these shares have not been registered under the Securities Act of 1933, as amended (the "Act"), they are restricted from sale until they are registered under the Act, or qualify for resale under the rules promulgated under the Act. All such shares were calculated at the trading closing price on the date of issuance. Stock Bonus Agreements From time to time, we issue shares of our common stock as a bonus for services rendered. Stock bonuses may be awarded upon satisfaction of specified performance goals pursuant to the Performance Stock Bonus Agreement. On each grant date, we valued the stock bonus based on the share price and the expenses were amortized using the straight line method. Total stock bonus expenses recorded during the three months ended March 31, 2016 and 2015 were $0 and $0, respectively and are reflected in operating expenses in the accompanying consolidated statements of operations.

NOTES PAYABLE - Note 8

NOTES PAYABLE - Note 8	3 Months Ended
NOTES PAYABLE - Note 8	Mar. 31, 2016
Notes to Financial Statements
NOTES PAYABLE - Note 8	NOTE 8 - NOTES PAYABLE Notes payable consisted of the following: March 31, December 31, 2016 2015 Promissory notes payable due to the former officers of MMRGlobal as part of severance packages, due in full on August 31, 2009 with no stated interest $ 76,783 $ 76,783 Promissory notes payable due to the former officers of MMRGlobal pursuant to the Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009 with no stated interest 25,444 25,444 Promissory notes payable due to vendors relating to settlement of certain outstanding accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009 and ending on January 27, 2011, with no stated interest 223,116 223,116 Short-term loan due to a third-party with 6% interest 44,070 44,070 369,413 369,413 Less: current portion (369,413) (369,413) Notes payable, less current portion $ - $ - Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest $ 6,743 $ 6,743 Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest 50,000 50,000 Notes payable related party, current portion 56,743 56,743 Less: current portion (56,743) (56,743) Notes payable related party, less current portion $ - $ -

CONVERTIBLE PROMISSORY NOTES -

CONVERTIBLE PROMISSORY NOTES - Note 9	3 Months Ended
CONVERTIBLE PROMISSORY NOTES - Note 9	Mar. 31, 2016
Notes to Financial Statements
CONVERTIBLE PROMISSORY NOTES - Note 9	NOTE 9 - CONVERTIBLE PROMISSORY NOTES From time to time, we issue Convertible Promissory Notes. As of March 31, 2016, a total of $323,749 in convertible notes remained outstanding. As of March 31, 2016, $198,749 of these Notes have matured, however, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of March 31, 2016. Each Note contains the following general terms and provisions: The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement. These notes bear interest at a rate of 6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option. During the first quarter of 2016, we did not enter into any Convertible Promissory Notes. Shares issuable upon conversion for convertible notes payable was 1,355,932 as of March 31, 2016. The total interest expense attributed to the Beneficial Conversion Feature of the Notes and related warrants for the three months ended March 31, 2016 and 2015 was $0 and $22,780, respectively.

RESTRUCTURING ACTIVITIES - Note

RESTRUCTURING ACTIVITIES - Note 10	3 Months Ended
RESTRUCTURING ACTIVITIES - Note 10	Mar. 31, 2016
Notes to Financial Statements
RESTRUCTURING ACTIVITIES - Note 10	NOTE 10 - RESTRUCTURING ACTIVITIES In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783. As of March 31, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.

RELATED PARTY TRANSACTIONS - No

RELATED PARTY TRANSACTIONS - Note 11	3 Months Ended
RELATED PARTY TRANSACTIONS - Note 11	Mar. 31, 2016
Notes to Financial Statements
RELATED PARTY TRANSACTIONS - Note 11	NOTE 11 - RELATED PARTY TRANSACTIONS Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 21.8% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Tenth Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above. The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made its President, Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities. In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference. We incurred $12,501 during the three months ended March 31, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $224,023 and $206,272 in related party payables as of March 31, 2016 and December 31, 2015, respectively, in connection with these services and board fees. We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the three months ended March 31, 2016 and 2015, the total expenses relating to this stockholder amounted to $30,000 and $30,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended March 31, 2016. As of March 31, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $135,000 and $130,000, respectively. On September 15, 2009, we entered into a five year agreement with E-Mail Frequency, LLC and David Loftus, Managing Partner of E-Mail Frequency, LLC, a significant stockholder of the Company, which was amended during 2011 to increase the term for an additional five years and provide licensor a non-exclusive right to target, market and exploit the Employee Benefits market We licensed an existing 80 million person direct marketing database (the "Database") of street addresses, cellular phone numbers, e-mail addresses and other comprehensive data with E-Mail Frequency. The agreement allows us to market, through the use of the Database, our MyMedicalRecords PHR, MyEsafeDepositBox virtual vault, and MMRPro document management system to physicians and their patients. Under the terms of the Agreement, we paid $250,000 to David Loftus as a one-time consulting fee in the form of 555,556 shares of our common stock. We recorded the $250,000 one-time licensee fee as a prepaid consulting fee, which was amortized over the service period. Included in related party payables at March 31, 2016 and December 31, 2015 is 129,230 in debt due to Mr. Loftus or to an affiliate of Mr. Loftus.

SUBSEQUENT EVENTS - Note 12

SUBSEQUENT EVENTS - Note 12	3 Months Ended
SUBSEQUENT EVENTS - Note 12	Mar. 31, 2016
Notes to Financial Statements
SUBSEQUENT EVENTS - Note 12	NOTE 12 - SUBSEQUENT EVENTS On May 12, 2016, the Board of Directors of MMRGlobal, Inc. elected Scott C. Kline to the Company's Board of Directors, increasing the current number of directors to six. Mr. Kline will also serve as a member of the Board of Directors of MyMedicalRecords, Inc. a wholly owned subsidiary of the Company. He is also acting as Secretary of the Corporation and will serve as General Counsel. Mr. Kline has served as outside Counsel to the Company since June of 2015. Mr. Kline was appointed to the Compensation Committee and Nominating and Corporate Governance Committee of the Board. The following is a summary of transactions by us since our previous disclosure on Form 10-K filed with the Securities and Exchange Commission on April 14, 2016 as amended by Form 10-K/A for the year ended December 31, 2015, as filed with the SEC on April 21, 2016 (together, the "Form 10-K") involving sales of our securities that were not registered under the Securities Act of 1933, as amended (the "Securities Act"). Each offer and sale was exempt from registration under either Section 4(2) of the Securities Act or Rule 506 under Regulation D of the Securities Act because (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each investor was given the opportunity to ask questions and receive answers concerning the terms of and conditions of the offering and to obtain additional information; (iv) the investors represented that they were acquiring the securities for their own account and for investment; and (v) the securities were issued with restrictive legends: On May 5, 2016, we granted an unrelated third party a warrant to acquire 7,500,000 shares of common stock in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 11, 2016, we granted a total of 3,100,000 shares of restricted stock to David Loftus, an affiliate of the Company, at a price of $0.02 per share in consideration of a reduction in debt. On May 11, 2016, we granted a total of 3,380,764 shares of restricted stock to Spanky LLC owned by David Loftus, an affiliate of the Company, at a price of $0.02 per in consideration of a reduction in debt. On May 12, 2016, The RHL Group, Inc., an entity affiliated with our Chairman & CEO Robert H. Lorsch, elected to purchase 5,000,000 shares of common stock at a price of $0.02 per share in consideration of partial waiver of principal amount under the Tenth Amended Note. On May 12, 2016, we granted Robert H. Lorsch, our Chairman & CEO, a warrant to acquire 10,000,000 shares of common stock in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Bernard Stolar, a Director and Acting Chief Financial Officer of the Company, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Bernard Stolar, a member of our Board of Directors and Acting Chief Financial Officer of the Company, a warrant to acquire 500,000 shares of common stock in consideration for services as Acting CFO. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Titus Day, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services in joining the Board on May 11, 2015. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Titus Day, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Mike Finley, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Scott Kline a warrant to acquire 500,000 shares of common stock in partial consideration of legal services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Scott Kline, appointed to the Company's Board of Directors on May 12, 2016, a warrant to acquire 1,000,000 shares of common stock in consideration for services in joining the Board. The warrant has an exercise price of $0.02 per share and vests after December 31, 2016, with an expiration date of January 2, 2020. On May 12, 2016, we granted Dr. Ivor Royston, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, and vests after December 31, 2016, with an expiration date of January 2, 2020. On May 12, 2016, we granted four warrants to acquire a combined total of 2,250,000 shares of common stock to individual employees of the Company in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 300,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 200,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 200,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 10,000,000 shares of common stock to an unrelated third party in consideration of legal services. The warrant has an exercise price of $0.04 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. All securities granted or sold under these agreements are unregistered and may only be resold or transferred if they later become registered or fall under an exemption to the Securities Act or applicable state laws. Our typical investor or grantee generally relies upon Rule 144 of the Securities Act, which, in addition to requiring several other conditions before resale may occur, requires that the securities issued be held for a minimum of six months. We generally used the proceeds of the foregoing sales of securities for repayment of indebtedness, working capital and other general corporate purposes.

Summary of Significant Accoun18

Summary of Significant Accounting Policies (Policies)	3 Months Ended
Summary of Significant Accounting Policies (Policies)	Mar. 31, 2016
Notes to Financial Statements
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of MMRGlobal, and its wholly-owned subsidiaries MMR and MMR Life Sciences Group, Inc. All intercompany transactions and balances are eliminated upon consolidation.
Basis of Presentation	Basis of Presentation We have prepared the accompanying consolidated unaudited financial statements in accordance with accounting principles generally accepted in the United States of America, or GAAP, for interim financial statements and with instructions to Form 10-Q pursuant to the rules and regulations of Securities and Exchange Act of 1934, as amended, or the Exchange Act and Article 8-03 of Regulation S-X promulgated under the Exchange Act. Accordingly, these financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of our management, we have included all adjustments considered necessary (consisting of normal recurring adjustments) for a fair presentation. Operating results for the three months ended March 31, 2016 are not indicative of the results that may be expected for the fiscal year ending December 31, 2016. You should read these unaudited condensed consolidated financial statements in conjunction with the audited financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2015.
Going Concern and Management's Plan	Going Concern and Management's Plan As of March 31, 2016, our current liabilities exceeded our current assets by $9.2 million. Furthermore, during the three months ended March 31, 2016, we incurred losses of $483,853, as further explained in Management's Discussion and Analysis of Financial Condition and Results of Operations appearing in Item 2 of Part I of this Quarterly Report on Form 10-Q. At March 31, 2016 and December 31, 2015, we had $0 and $0, respectively, in cash and cash equivalents. Historically, we issued capital stock, sold debt and equity securities and received funds from The RHL Group, Inc. (a significant stockholder that is wholly-owned by our Chairman and Chief Executive Officer, Robert H. Lorsch) to operate our business. Although we received additional funding from The RHL Group pursuant to the Tenth Amended and Restated Note effective May 20, 2015 (the "Line of Credit"), we will still be required to obtain additional financing in order to meet installment payment obligations and the previously existing obligations under the Line of Credit, which had a balance of $2,362,633 at March 31, 2016 and a total Unpaid Balance (as defined in the Line of Credit) of $2,612,633, which includes amounts borrowed under the Line of Credit, unpaid interest fees, any amounts guaranteed by The RHL Group, and other obligations due The RHL Group pursuant to the terms of the Tenth Amended and Restated Note and the Security Agreement. As a result of the above, we express uncertainty about our ability to continue as a going concern. The components of the RHL Group Note payable and the related balance sheet presentation as of March 31, 2016 are as follows: $1,360,682, which is included in the line of credit, related party; and $1,001,950 related to other obligations due to The RHL Group which are included in related party payables. Management's plan regarding this matter is to, amongst other things, continue to utilize our available line of credit with The RHL Group (see Note 3). As of March 31, 2016, we had approximately $1,887,367 remaining as available under The RHL Group line of credit. Additionally, we plan to continue selling additional debt and equity securities, continue to settle our existing liabilities through issuance of equity securities, explore other debt financing arrangements, continue to increase our existing subscriber and affiliate customer base, sell MMRPro products, and continue licensing our intellectual property to obtain additional cash flow over the next twelve months. We cannot assure that funds from these sources will be available when needed or, if available, will be on terms favorable to us or to our stockholders. If we raise additional funds or settle liabilities by issuing equity securities, the percentage ownership of our stockholders will be reduced, stockholders may experience additional dilution or such equity securities may provide for rights, preferences or privileges senior to those of the holders of our common stock. If we are unable to utilize our available line of credit with The RHL Group or obtain suitable alternative debt or equity financing, our ability to execute our business plan and continue as a going concern may be adversely affected. These matters raise substantial doubt about our ability to continue as a going concern. These financial statements were prepared under the assumption that we will continue as a going concern and do not include any adjustments that might result from the outcome of that uncertainty.
Management's Use of Estimates	(a) MANAGEMENT'S USE OF ESTIMATES The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses during each reporting period. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, allowances for doubtful accounts, the valuation of deferred income taxes, tax contingencies, long-lived and intangible assets, valuation of derivative liabilities and stock-based compensation. These estimates are based on historical experience and on various other factors that management believes to be reasonable under the circumstances, although actual results could differ from those estimates.
Cash and Cash Equivalents	(b) CASH AND CASH EQUIVALENTS We consider cash equivalents to be only those investments that are highly liquid, readily convertible to cash and with maturities of 90 days or less at the purchase date. We maintain our cash in bank deposit accounts that, at times, may exceed federally insured limits. We have not experienced any losses in such accounts and believe that we are not exposed to any significant credit or deposit risk on our cash. We had cash and cash equivalents of $0 and $0 as of March 31, 2016 and December 31, 2015, respectively.
Trade and Other Receivables	(c) TRADE AND OTHER RECEIVABLES Receivables represent claims against third parties that will be settled in cash. The carrying value of receivables, net of an allowance for doubtful accounts, if any, represents their estimated net realizable value. We estimate the allowance for doubtful accounts, if any, based on historical collection trends, type of customer, the age of outstanding receivables and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, we give further consideration to the collectability of those balances and the allowance is adjusted accordingly. We write off past due receivable balances when collection efforts have been unsuccessful in collecting the amount due.
Fair Value of Financial Instruments	(e) FAIR VALUE OF FINANCIAL INSTRUMENTS ASC 820-10, Fair Value Measurements and Disclosures, We utilize ASC 820-10 for valuing financial assets and liabilities measured on a recurring basis. ASC 820-10 defines fair value, establishes a framework for measuring fair value and generally accepted accounting principles, and expands disclosures about fair value measurements. This standard applies in situations where other accounting pronouncements either permit or require fair value measurements. ASC 820-10 does not require any new fair value measurements. Accounting guidance also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The standard describes three levels of inputs that may be used to measure fair value: Level 1: Quoted prices in active markets for identical or similar assets and liabilities. Level 2: Quoted prices for identical or similar assets and liabilities in markets that are not active or observable inputs other than quoted prices in active markets for identical or similar assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Impairment of Long-Lived Assets and Intangibles	(e) IMPAIRMENT OF LONG-LIVED ASSETS AND INTANGIBLES We account for long-lived assets, which include property and equipment and identifiable intangible assets with finite useful lives (subject to amortization), in accordance with ASC 350-30. ASC 350-30 requires that we review long-lived assets for impairment whenever events or changes in circumstances indicate that we may not recover the carrying amount of an asset. We measure recoverability by comparing the carrying amount of an asset to the expected future undiscounted net cash flows generated by the asset. If we determine that the asset may not be recoverable, or if the carrying amount of an asset exceeds its estimated future undiscounted cash flows, we recognize an impairment charge to the extent of the difference between the fair value and the asset's carrying amount. Our assessment of the undiscounted future cash flows indicated that the carrying amount of the long-lived and intangible assets are recoverable, therefore, we had no impairment charges during the three months ended March 31, 2016 and 2015.
Revenue Recognition	(f) REVENUE RECOGNITION We generate our revenues from services, which are comprised of providing electronic access to consumer medical records and other vital documents, and from the licensing of our intellectual property and services. We recognize revenue only when the price is fixed or determinable, persuasive evidence of an arrangement exists, the service is performed, and we are reasonably assured of collectability of the resulting receivable. Our subscriber revenues consist of annual and monthly recurring retail subscriptions and usage-based fees, which are primarily paid in advance by credit card, and corporate accounts that are based on either an access-fee or actual number of users, and in each case billed in advance at the beginning of each month of service. We defer the portions of annual recurring subscription fees collected in advance and recognize them on a straight line basis over the subscription period. We license the rights to use portions of our intellectual property portfolio, which includes certain patent rights essential to the sale of certain PHR products. Licensees typically pay a license fee in one or more installments and ongoing royalties based on their sales of products incorporating or using the Company's licensed intellectual property. License fees are recognized over the estimated period of benefit to the licensee, typically five to fifteen years. The Company earns royalties on such licensed products sold by its licensees at the time that the licensees' sales occur. The Company recognizes royalty revenues based on royalties reported by licensees during the quarter and when other revenue recognition criteria are met. We grant exclusive and non-exclusive licenses for the sale and marketing of our services in international territories in consideration of license fees and ongoing royalties. The royalty fee is usually a percentage of revenue earned by the licensee and there are usually certain minimum guarantees. We defer the recognition of license fee revenues received in advance from international licensees for the grant of the license and recognize them over the period covered by the agreement. We defer the recognition of minimum guaranteed royalty payments received in advance and recognize them over the period to which the royalty relates. We include all such revenues under "License Fees." In those cases where a license agreement contains multiple deliverables, we account for the agreement in accordance with ASC 605-25 - Revenue Recognition - Multiple-Element Arrangements We recognize revenue on sales of our MMRPro system in accordance with ASC 605-25, Revenue Recognition, Multiple-Element Arrangements Our multiple-deliverable arrangements consist solely of our MMRPro product. Significant deliverables within these arrangements include sophisticated scanning equipment, various licenses to use third party software, a license to use our proprietary MMRPro application software, installation and training, dedicated telephone lines, secure online storage and warranties. We determined all elements to be separate units of accounting as they have standalone value to the customers and/or they are sold by other vendors on a standalone basis. Delivery of the hardware and certain software elements of these arrangements occur at the inception of the agreement. We deliver installation and training at the inception of the agreement. We provide other software licenses, telephone lines and online secure storage over the three year term of the agreement. We include warranties in the arrangements, however the third party product manufacturer, and not us, is obligated to fulfill such warranties. The third-party warranty contracts are paid in advance and are not refundable. We allocate the revenue derived from these arrangements among all the deliverables. We base such allocation on the relative selling price of each deliverable. With the exception of our proprietary MMRPro application software, we use third party evidence to set the selling prices used for this allocation. In all such cases, third parties sell the same or very similar products. For the MMRPro application software, we estimate the selling price based on recent discussions regarding licensure of that particular application on a standalone basis. To date, we have not licensed this software on a standalone basis. We recognize the allocated revenue for each deliverable in accordance with SEC Staff Accounting Bulletin ("SAB") No. 104, Topic 13: Revenue Recognition Revenue from the licensing of our biotech assets may include non-refundable license and up-front fees, non- refundable milestone payments that are triggered upon achievement of a specific event, and future royalties or lump-sum payments on sales of related products. For agreements that provide for milestone payments, we adopted ASC 605-28-25, Revenue Recognition Milestone Method.
Shared-Based Compensation	(g) SHARE-BASED COMPENSATION We account for share-based compensation in accordance with ASC 718-20, Awards Classified as Equity We account for options and warrants issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees We estimate the fair value of each stock option on the date of grant using the Black-Scholes option pricing model. We determine assumptions relative to volatility and anticipated forfeitures at the time of grant. No stock options were granted during the three months ended March 31, 2016. We valued grants of stock options and warrants during the three months ended March 31, 2015 using the following assumptions. Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0% We base the assumptions used in the Black-Scholes models upon the following data: (1) our use of the contractual life of the underlying non-employee warrants as the expected life; the expected life of the employee options used in this calculation is the period of time the options are expected to be outstanding and has been determined based on historical exercise experience; (2) in the absence of an extensive public market for our shares, the expected stock price volatility of the underlying shares over the expected term of the option or warrant was taken at approximately the mid-point of the range for similar companies at the various grant dates; (3) we base the risk free interest rate on published U.S. Treasury Department interest rates for the expected terms of the underlying options or warrants; (4) we base expected dividends on historical dividend data and expected future dividend activity; and (5) we base the expected forfeiture rate on historical forfeiture activity and assumptions regarding future forfeitures based on the composition of current grantees.
Net Income/Loss Per Share	(h) NET INCOME/LOSS PER SHARE We apply the guidance of ASC 260-10, Earnings Per Share We excluded all potential anti-dilutive common shares from the computation of diluted net loss per common share for the three months ended March 31, 2016 and 2015 because they were anti-dilutive due to our net loss position. Stock options, warrants and convertible notes excluded from the computation totaled 20,272,887 shares for the three months ended March 31, 2016 and 29,791,116 shares for the three months ended March 31, 2015, respectively.
Recent Accounting Pronouncements	(i) RECENT ACCOUNTING PRONOUNCEMENTS In May 2014, the Financial Accounting Standards Board issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers In August 2014, the FABS issued ASU No. 2014-15, Disclosure of Uncertainties about an Entity's Ability to Continue as a Going Concern In February 2015, the FASB issued ASU 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis In April 2015, the FASB issued ASU No 2015-3, Simplifying the Presentation of Debt Issuance Costs. In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting In April 2016, the FASB issued AS 2016-10, Revenue from Contracts with Customers (Topic 606)
Reclassifications	(j) RECLASSIFICATIONS Certain numbers in the prior year have been reclassified to conform to the current year's presentation.
Income Taxes	Under ASC 740-270, Income Taxes - Interim Reporting Pursuant to ASC 740, Income MMR Inc., in its capacity as the operating company taking over our income tax positions in addition to its own positions after January 27, 2009 (see Note 1), has estimated its annual effective tax rate to be zero. MMRGlobal has based this on an expectation that the combined entity will generate net operating losses in 2016, and it is not likely that those losses will be recovered using future taxable income. Therefore, no provision for income tax has been recorded as of and for the three months ended March 31, 2016. We account for income taxes in accordance with ASC 740-10, Income Taxes

SHARE-BASED COMPENSATION (Table

SHARE-BASED COMPENSATION (Tables)	3 Months Ended
SHARE-BASED COMPENSATION (Tables)	Mar. 31, 2016
Share-based Compensation Tables
Schedule of Valuation Assumptions to Determine the Fair Value of Stock Options	We valued grants of stock options and warrants during the three months ended March 31, 2015 using the following assumptions. Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	3 Months Ended
COMMITMENTS AND CONTINGENCIES (Tables)	Mar. 31, 2016
Commitments And Contingencies Tables
Schedule of Future Minimum Rental Payments for Operating and Capital Leases	Future minimum lease payments as of March 31, 2016, under non-cancelable operating leases (with initial or remaining lease terms in excess of one year) are as follows: Year Ending Operating Capital December 31, Leases Leases 2016 (Remainder of) $ 142,175 $ 13,222 2017 206,305 - 2018 146,410 - Total minimum lease payments $ 494,890 $ 13,222

EQUITY ISSUANCES (Tables)

EQUITY ISSUANCES (Tables)	3 Months Ended
EQUITY ISSUANCES (Tables)	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Outstanding Option Awards	A summary of option activity for the three months ended March 31, 2016 is presented below. Options granted by MMR Inc. prior to the date of the Merger have been retroactively restated to reflect the conversion ratio of MMR Inc. to MMR shares. Weighted-Average Weighted- Remaining Average Contractual Aggregate Exercise Life Intrinsic Options Price (Years) Value Outstanding at December 31, 2015 7,488,345 $ 0.50 3.62 $ - Granted - - Exercised - - Cancelled - $ - Outstanding at March 31, 2016 (Unaudited) 7,488,345 $ 0.50 3.38 $ - Vested and expected to vest at March 31, 2016 (Unaudited) 7,488,345 $ 0.50 3.38 $ - Exercisable at March 31, 2016 (Unaudited) 7,348,345 $ 0.50 3.34 $ -
Summary of Stock Options Outstanding and Exercisable	The following table summarizes information about stock options outstanding and exercisable at March 31, 2016. Options Outstanding Options Exercisable Weighted Weighted Weighted Weighted Average Average Average Average Exercise Number Remaining Exercise Number Remaining Exercise Price of Shares Life (Years) Price of Shares Life (Years) Price $ 0.25 - 0.45 2,560,000 5.56 $ 0.35 2,420,000 5.57 $ 0.30 $ 0.50 - 0.75 4,602,292 2.19 $ 0.55 4,602,292 2.19 $ 0.55 $ > 0.75 326,053 2.39 $ 0.90 326,053 2.39 $ 0.90 7,488,345 7,348,345
Summary of Outstanding Warrant Awards	A summary of the activity of our warrants for the three months ended March 31, 2016 is presented below: Weighted Avg Shares Exercise Price Outstanding at December 31, 2015 11,428,610 $ 0.30 Granted - - Exercised - - Cancelled (850,000) 0.56 Outstanding at March 31, 2016 (Unaudited) 10,578,610 $ 0.28 Exercisable at March 31, 2016 (Unaudited) 10,511,944 $ 0.28
Black-Scholes option and valuation model assumptions	We valued grants of stock options and warrants during the three months ended March 31, 2015 using the following assumptions. Expected life in years 2 - 5 Years Stock price volatility 120.51% - 122.72% Risk free interest rate 0.04 - 1.38% Expected dividends None Forfeiture rate 0%
Shares Issued for Services or Reduction to Liabilities	During the three months ended March 31, 2016, we issued 9,742,050 shares of common stock with a value of $146,131 to various third parties and charged the proceeds to the appropriate accounts for the following reasons: Three Months Ended March 31, 2016 Purpose Shares Value Services provided - $ - Reduction of payables 9,742,050 146,131 Totals 9,742,050 $ 146,131

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
NOTES PAYABLE (Tables)	Mar. 31, 2016
Notes Payable Tables
Notes Payable	Notes payable consisted of the following: March 31, December 31, 2016 2015 Promissory notes payable due to the former officers of MMRGlobal as part of severance packages, due in full on August 31, 2009 with no stated interest $ 76,783 $ 76,783 Promissory notes payable due to the former officers of MMRGlobal pursuant to the Resignation and Post-Merger Employment Arrangement, due in full on August 31, 2009 with no stated interest 25,444 25,444 Promissory notes payable due to vendors relating to settlement of certain outstanding accounts payable, payable in 18 equal monthly installments commencing on July 27, 2009 and ending on January 27, 2011, with no stated interest 223,116 223,116 Short-term loan due to a third-party with 6% interest 44,070 44,070 369,413 369,413 Less: current portion (369,413) (369,413) Notes payable, less current portion $ - $ - Short term loan due to a related-party, payable in full on January 2, 2014 with 12% interest $ 6,743 $ 6,743 Short term loan due to a related-party, payable in full on May 31, 2014 with 12% interest 50,000 50,000 Notes payable related party, current portion 56,743 56,743 Less: current portion (56,743) (56,743) Notes payable related party, less current portion $ - $ -

Accounting Policies (Cash and C

Accounting Policies (Cash and Cash Equivalents) (Narrative) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015	Mar. 31, 2015	Dec. 31, 2014
Accounting Policies Cash And Cash Equivalents Narrative Details
Cash and cash equivalents	$ 0	$ 0	$ 0	$ 309,393

Accounting Policies (Intangible

Accounting Policies (Intangible Assets and Impairments) (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Accounting Policies Intangible Assets And Impairments Narrative Details
Impairment charges	$ 0	$ 0

Accounting Policies (Share-Base

Accounting Policies (Share-Based Compensation Schedule Of Assumptions Used In Black-Scholes Model) (Details)	3 Months Ended
	Mar. 31, 2015USD ($)
Accounting Policies Share-based Compensation Schedule Of Assumptions Used In Black-scholes Model Details
Expected life, in years, maximum	5 years
Stock price volatility, minimum	120.51%
Stock price volatility, maximum	122.72%
Risk-free interest rate, mimimum	0.40%
Risk-free interest rate, maximum	1.38%
Expected dividends	$ 0
Forfeiture rate	0.00%

Related Party Note Payable (Nar

Related Party Note Payable (Narrative) (Details) - Tenth Amended and Restated Secured Promissory Note - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Date of note	May 20, 2015
Maximum line of credit under note	On May 20, 2015, we and The RHL Group entered into a Tenth Amended and Restated Promissory Note (the " Amended Note Existing Note Credit Facility Historically, the predecessor notes have increased over time the maximum amount of credit available under the Credit Facility from $100,000 to $1,000,000 to $3,000,000 to $4,500,000. The maximum amount of the Amended Note is $4,500,000. The Amended Note continues to bear interest at the lesser of 10% or the highest rate then permitted by law, and is secured (similar to the Existing Note) by a Security Agreement, which has been in effect since July 31, 2007, as renewed and amended to date (the "Security Agreement"). The Tenth Amended Note had a current balance of $2,362,633 at March 31, 2016. The components of the Tenth Amended Note and the related balance sheet presentation as of March 31, 2016 are as follows: $1,360,682, which is included in the line of credit, related party; and $1,001,951 for other obligations due to The RHL Group, which is included in related party payables. Total interest expense on the Line of Credit for the three months ended March 31, 2016 and 2015 amounted to $68,973 and $30,676, respectively. The unpaid interest balances as of March 31, 2016 and December 31, 2015 were $189,739 and $60,257, respectively. In conjunction with the Tenth Amended Note, we were required to maintain certain financial covenants, including the requirement that we have at least $200,000 of cash in our bank accounts or such other amount as necessary to maintain operations through the subsequent thirty (30) days and timely pay any obligations due respecting payroll and all associated payroll taxes on and after March 31, 2016. Since we did not meet these covenants as of March 31, 2016, we received a second waiver from The RHL Group until June 1, 2016.
Maturity date	Apr. 29, 2016
Warrants granted for shares	352,928
Warrant price per share	$ 0.015
Debt component classification:
Line of credit, related party	$ 1,360,682
Related party payables	1,001,951
Total note payable balance	2,362,633
Interest expense on line of credit	68,973	$ 30,676
Related party accrued interest	$ 189,739		$ 60,257

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details)	3 Months Ended
Income Taxes (Narrative) (Details)	Mar. 31, 2016USD ($)
Income Taxes Narrative Details
Unrecognized tax benefits	$ 0
Income tax rate	0.00%

Commitments and Contingencies28

Commitments and Contingencies (Operating Leases) (Details)	Mar. 31, 2016USD ($)
Year ending December 31:
2016 (Remainder of)	$ 142,175
2,017	206,305
2,018	146,410
Total minimum lease payments	$ 494,890

Commitments and Contingencies29

Commitments and Contingencies (Capital Leases) (Details)	Mar. 31, 2016USD ($)
Year ending December31:
2016 (Remainder of)	$ 13,222
Total minimum lease payments	$ 13,222

Commitments and Contingencies30

Commitments and Contingencies (Leases Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Rent expense	$ 26,445	$ 30,670
September 2013 Lease
Operating lease description	Effective September 1, 2013, we renewed our lease for office space in Los Angeles, California with a term through August 31, 2018. The lease currently requires a monthly payment of $8,250.

Equity Issuances (Stock Option

Equity Issuances (Stock Option Activity Summary Of Option Activity) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Equity Issuances Stock Option Activity Summary Of Option Activity Details
Outstanding at December 31, 2015	7,488,345
Granted	0
Exercised	0
Cancelled	0
Outstanding at March 31, 2016 (Unaudited)	7,488,345
Vested and expected to vest at March 31, 2016 (Unaudited)	7,488,345
Exercisable at June 30, 2015 (Unaudited)	7,348,345
Weighted-Average Exercise Prices, Outstanding at December 31, 2015 \| $ / shares	$ 0.50
Weighted-Average Exercise Prices, Granted \| $ / shares	0
Weighted-Average Exercise Prices, Exercised \| $ / shares	0
Weighted-Average Exercise Prices, Forfeited, cancelled or expired \| $ / shares	0
Weighted-Average Exercise Prices, Outstanding March 31, 2016 \| $ / shares	0.50
Weighted-Average Exercise Prices, Vested and expected to vest \| $ / shares	$ 0.50
Weighted-Average Remaining Contractual Life (in years), Outstanding at December 31, 2015	3 years 223 days
Weighted-Average Remaining Contractual Life (in years), Outstanding at March 31, 2016	3 years 137 days
Weighted-Average Remaining Contractual Life (in years), Vested and expected to vest	3 years 137 days
Weighted-Average Remaining Contractual Life (in years), Exercisable	3 years 122 days
Aggregate Intrinsic Value, Outstanding at December 31, 2015 \| $	$ 0
Aggregate Intrinsic Value, Outstanding at March 31, 2016 \| $	0
Aggregate Intrinsic Value, Vested and expected to vest \| $	0
Aggregate Intrinsic Value, Exercisable \| $	$ 0

Equity Issuances (Stock Optio32

Equity Issuances (Stock Option Activity Summary Of Stock Options Outstanding and Exercisable) (Details) - $ / shares	3 Months Ended
	Mar. 31, 2016	Dec. 31, 2015
Options Outstanding, Number of Shares	7,488,345	7,488,345
Options Outstanding, Weighted-Average Exercise Price Per Share	$ 0.50	$ 0.50
Options Exercisable, Number of Shares	7,348,345
$0.25 - $0.45
Range of Exercise Price, Minimum	$ 0.25
Range of Exercise Price, Maximum	$ 0.45
Options Outstanding, Number of Shares	2,560,000
Options Outstanding, Weighted-Average Remaining Life (in years)	5 years 202 days
Options Outstanding, Weighted-Average Exercise Price Per Share	$ 0.35
Options Exercisable, Number of Shares	2,420,000
Options Exercisable, Weighted-Average Remaining Life (in years)	5 years 205 days
Options Exercisable, Weighted-Average Exercise Price Per Share	$ 0.30
$0.50 - $0.75
Range of Exercise Price, Minimum	0.50
Range of Exercise Price, Maximum	$ 0.75
Options Outstanding, Number of Shares	4,602,292
Options Outstanding, Weighted-Average Remaining Life (in years)	2 years 68 days
Options Outstanding, Weighted-Average Exercise Price Per Share	$ 0.55
Options Exercisable, Number of Shares	4,602,292
Options Exercisable, Weighted-Average Remaining Life (in years)	2 years 68 days
Options Exercisable, Weighted-Average Exercise Price Per Share	$ 0.55
> $0.75
Range of Exercise Price, Minimum	$ 0.75
Options Outstanding, Number of Shares	326,053
Options Outstanding, Weighted-Average Remaining Life (in years)	2 years 140 days
Options Outstanding, Weighted-Average Exercise Price Per Share	$ 0.90
Options Exercisable, Number of Shares	326,053
Options Exercisable, Weighted-Average Remaining Life (in years)	2 years 140 days
Options Exercisable, Weighted-Average Exercise Price Per Share	$ 0.90

Equity Issuances (Stock Optio33

Equity Issuances (Stock Option and Warrant Expense Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Equity Issuances Stock Option And Warrant Expense Narrative Details
Stock option expense	$ 5,586	$ 5,525
Warrant expense	$ 2,352	$ 5,490

Equity Issuances (Summary Of Wa

Equity Issuances (Summary Of Warrant Activity) (Details)	3 Months Ended
Equity Issuances (Summary Of Warrant Activity) (Details)	Mar. 31, 2016$ / sharesshares
Equity Issuances Summary Of Warrant Activity Details
Warrants outstanding at December 31, 2015 \| shares	11,428,610
Granted \| shares	0
Exercised \| shares	0
Cancelled \| shares	(850,000)
Warrants exercisable at March 31, 2016 \| shares	10,511,944
Weighted-average exercise price, beginning balance	$ 0.30
Weighted-average exercise price, granted	0
Weighted-average exercise price, exercised during period	0
Weighted-average exercise price, cancelled during period	0.56
Weighted-average exercise price, ending balance	0.28
Warrants exercisable, weighted average exercise price	$ 0.28

Equity Issuances (Summary Of 35

Equity Issuances (Summary Of Warrants Outstanding and Exercisable) (Details)	3 Months Ended
	Mar. 31, 2016$ / sharesshares
Warrants exercisable \| shares	10,511,944
$0.02 - $0.30
Range of Exercise Price, Minimum	$ 0.02
Range of Exercise Price, Maximum	$ 0.30
Warrants outstanding at March 31, 2016 \| shares	8,182,798
Warrants outstanding, Weighted-average remaining life, in years	1 year 151 days
Warrants outstanding, Weighted-average exercise price	$ 0.20
Warrants exercisable \| shares	8,116,131
Warrants exercisable, Weighted-average remaining life, in years	1.41
Warrants exercisable, Weighted-average exercise price	$ 0.20
$0.30 - $0.50
Range of Exercise Price, Minimum	0.30
Range of Exercise Price, Maximum	$ 0.50
Warrants outstanding at March 31, 2016 \| shares	255,000
Warrants outstanding, Weighted-average remaining life, in years	1 year 11 days
Warrants outstanding, Weighted-average exercise price	$ 0.50
Warrants exercisable \| shares	255,000
Warrants exercisable, Weighted-average remaining life, in years	1.03
Warrants exercisable, Weighted-average exercise price	$ 0.50
> $0.50
Range of Exercise Price, Minimum	$ 0.50
Warrants outstanding at March 31, 2016 \| shares	2,140,812
Warrants outstanding, Weighted-average remaining life, in years	198 days
Warrants outstanding, Weighted-average exercise price	$ 0.75
Warrants exercisable \| shares	2,140,812
Warrants exercisable, Weighted-average remaining life, in years	0.55
Warrants exercisable, Weighted-average exercise price	$ 0.75

Equity Issuances (Inputs Used I

Equity Issuances (Inputs Used In Black-Scholesl) (Details)	3 Months Ended
Equity Issuances (Inputs Used In Black-Scholesl) (Details)	Mar. 31, 2015USD ($)
Equity Issuances Inputs Used In Black-scholesl Details
Expected life, in years, maximum	5 years
Stock price volatility, minimum	120.51%
Stock price volatility, maximum	122.72%
Risk-free interest rate, minimum	0.40%
Risk-free interest rate, maximum	1.38%
Expected dividends	$ 0
Forfeiture rate	0.00%

Equity Issuances (Shares Issued

Equity Issuances (Shares Issued for Services or Reduction to Liabilities) (Details)	3 Months Ended
	Mar. 31, 2016USD ($)shares
Equity Issuances Shares Issued For Services Or Reduction To Liabilities Details
Reduction of payables, shares \| shares	9,742,050
Reduction of payables, amount \| $	$ 146,131
Services provided, shares \| shares	0
Services provided, amount \| $	$ 0
Total payment of services provided through issuance of common stock, shares \| shares	9,742,050
Total payment of accounts payable through issuance of common stock, amount \| $	$ 146,131

Equity Issuances (Stock Bonus A

Equity Issuances (Stock Bonus Agreements) (Narrative) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Stock Bonus Agreement expense	$ 0	$ 0

Notes Payable (Details)

Notes Payable (Details) - USD ($)	3 Months Ended
Notes Payable (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Notes payable consisted of the following:
Short-term debt	$ 369,413	$ 369,413
Related party short-term debt	$ 56,743	56,743
Severance Package Notes
Notes payable consisted of the following:
Short-term Debt, Terms	Promissory notes payable due to the former officers of MMRGlobal as part of severance packages, due in full on August 31, 2009 with no stated interest
Short-term debt	$ 76,783	76,783
Resignation and Post-Merger Employment Arrangement Notes
Notes payable consisted of the following:
Short-term Debt, Terms	Promissory notes payable due to the former officers of
Short-term debt	$ 25,444	25,444
Notes Payable - Vendors
Notes payable consisted of the following:
Short-term Debt, Terms	Promissory notes payable due to vendors relating to settlement of certain
Short-term debt	$ 223,116	223,116
Short Term Loan Two
Notes payable consisted of the following:
Short-term Debt, Terms	Short term loan due to a third-party with no stated interest
Short-term debt	$ 44,070	44,070
Related Party One
Notes payable consisted of the following:
Short-term Debt, Terms	Short term loan due to a related-party, payable in full on
Related party short-term debt	$ 50,000	50,000
Related Party Two
Notes payable consisted of the following:
Short-term Debt, Terms	Short term loan due to a related-party, payable in full on
Related party short-term debt	$ 6,743	$ 6,743

Convertible Promissory Notes (N

Convertible Promissory Notes (Narrative) (Details)	3 Months Ended
Convertible Promissory Notes (Narrative) (Details)	Mar. 31, 2016USD ($)	Mar. 31, 2015USD ($)
Convertible Promissory Notes Narrative Details
Debt instrument, description	From time to time, we issue Convertible Promissory Notes. As of March 31, 2016, a total of $323,749 in convertible notes remained outstanding. As of March 31, 2016, $198,749 of these Notes have matured, however, the Company and the Holders have agreed to keep the balance as a Note Payable and the note holders have elected not to convert their note balances into shares of our common stock as of March 31, 2016. Each Note contains the following general terms and provisions: The principal amount owed under each note becomes due and payable one year or less from the investment date provided that, upon ten (10) days' prior written notice to the holder, we may, in our sole discretion, extend the maturity date for an additional six month term. The Notes can be further extended upon mutual agreement. These notes bear interest at a rate of 6% per annum payable in cash or shares of common stock or a combination of cash and shares of common stock at our option.
Debt Instrument, Convertible, Number of Equity Instruments	1,355,932
Interest expense	$ 0	$ 22,780

Restructuring Activities (Narra

Restructuring Activities (Narrative) (Details) - USD ($)	3 Months Ended
Restructuring Activities (Narrative) (Details) - USD ($)	Mar. 31, 2016	Dec. 31, 2015
Total remaining severance liability	$ 620,613	$ 620,613
Favrille
Restructuring and Related Activities, Description	In connection with the merger with Favrille, Inc. in 2009, we signed promissory notes with certain former executives totaling $76,783. As of March 31, 2016, the total remaining severance liabilities amounted to $620,613, which is reflected as severance liability on the accompanying consolidated balance sheets. This consists of $571,362 payable to former non-executive employees.
Promissory notes with certain former executives	$ 76,783
Severance liabilty payable to former non-executive employees in 18 monthly installments starting on July 27, 2009	571,362
Estimated payroll tax on severance liabilty	49,251
Total remaining severance liability	$ 620,613

Related Party Transactions (Nar

Related Party Transactions (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
Related Party Transactions (Narrative) (Details) - USD ($)	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2009	Dec. 31, 2015
Related party payables	$ 1,575,881			$ 1,385,901
The RHL Group, Inc.
Nature of Common Ownership or Management Control Relationships	Our Chairman and Chief Executive Officer, Robert H. Lorsch, is also the Chief Executive Officer of The RHL Group, Inc. and has full voting power over all of the capital stock of The RHL Group, Inc. Mr. Lorsch directly and indirectly through The RHL Group, Inc., beneficially owns approximately 21.8% our total outstanding voting stock. The RHL Group, Inc. has loaned us money pursuant to the Tenth Amended Note and all predecessor notes. See Note 3 - Related Party Note Payable above. The RHL Group is an investment holding company which provides consulting, operational and technical services to us, which we refer to as the RHL Services. As part of the RHL Services, The RHL Group provides us with unrestricted access to its internal business and relationship contact database of more than 10,000 persons and entities, which includes clients of The RHL Group and other individuals which may hold value to us. The RHL Group also provides infrastructure support to us, including allowing us unlimited access to its facilities, equipment, and data, information management and server systems. In addition to allowing us the use of its office support personnel, The RHL Group has also consented to allow us to utilize the full-time services of Mr. Lorsch as our President, Chairman and Chief Executive Officer, which requires substantial time and energy away from his required duties as The RHL Group's Chairman and Chief Executive Officer. In addition, The RHL Group has made its President, Kira Reed, available as our spokesperson. Ms. Reed, who is Mr. Lorsch's spouse, also manages our social networking activities. In consideration for the above, The RHL Group, Inc. has a consulting arrangement with MMR. A copy of the consulting agreement is filed as an exhibit in our Form 8-K, as filed with the SEC on May 4, 2009 and is hereby incorporated by reference.
Bernard Stolar
Nature of Common Ownership or Management Control Relationships	We incurred $12,501 during the three months ended March 31, 2016 and 2015, toward marketing consulting services from Bernard Stolar, a director. We included $224,023 and $206,272 in related party payables as of March 31, 2016 and December 31, 2015, respectively, in connection with these services and board fees.
Related Party Transaction, Expenses from Transactions with Related Party	$ 12,501	$ 12,500
Related party payables	$ 224,023			206,272
Significant Vendor
Nature of Common Ownership or Management Control Relationships	We contract with a significant vendor for the development and maintenance of the software applications necessary to run our MyMedicalRecords PHR, MyEsafeDepositBox and MyMedicalRecords Pro products. Our outside developer supports our software development needs through a team of software engineers, programmers, quality control personnel and testers, who work with our internal product development team on all aspects of application development, design, integration and support of our products. This vendor is also a stockholder. For the three months ended March 31, 2016 and 2015, the total expenses relating to this stockholder amounted to $30,000 and $30,000, respectively. In addition, we capitalized $0 of software development costs for the quarter ended March 31, 2016. As of March 31, 2016 and December 31, 2015, the total amounts due to the stockholder and included in related party payables amounted to $135,000 and $130,000, respectively.
Related Party Transaction, Expenses from Transactions with Related Party	$ 30,000	30,000
Related party payables	$ 135,000			130,000
E-Mail Frequency, LLC
Nature of Common Ownership or Management Control Relationships	On September 15, 2009, we entered into a five year agreement with E-Mail Frequency, LLC and David Loftus, Managing Partner of E-Mail Frequency, LLC, a significant stockholder of the Company, which was amended during 2011 to increase the term for an additional five years and provide licensor a non-exclusive right to target, market and exploit the Employee Benefits market We licensed an existing 80 million person direct marketing database (the "Database") of street addresses, cellular phone numbers, e-mail addresses and other comprehensive data with E-Mail Frequency. The agreement allows us to market, through the use of the Database, our MyMedicalRecords PHR, MyEsafeDepositBox virtual vault, and MMRPro document management system to physicians and their patients. Under the terms of the Agreement, we paid $250,000 to David Loftus as a one-time consulting fee in the form of 555,556 shares of our common stock. We recorded the $250,000 one-time licensee fee as a prepaid consulting fee, which was amortized over the service period. Included in related party payables at March 31, 2016 and December 31, 2015 is 129,230 in debt due to Mr. Loftus or to an affiliate of Mr. Loftus.
Related Party Transaction, Expenses from Transactions with Related Party	$ 0	0
Amortization of licensee fee	0	37,500
David Loftus
Related party payables	129,230			$ 129,230
Shares issued for services, related party, shares			555,556
Shares issued for services, related party, amount			$ 250,000
Interest expense with related party	$ 0	$ 0

Subsequent Events (Narrative) (

Subsequent Events (Narrative) (Details)	3 Months Ended
Subsequent Events (Narrative) (Details)	Mar. 31, 2016
Subsequent Events Narrative Details
Subsequent Event, Description	On May 12, 2016, the Board of Directors of MMRGlobal, Inc. elected Scott C. Kline to the Company's Board of Directors, increasing the current number of directors to six. Mr. Kline will also serve as a member of the Board of Directors of MyMedicalRecords, Inc. a wholly owned subsidiary of the Company. He is also acting as Secretary of the Corporation and will serve as General Counsel. Mr. Kline has served as outside Counsel to the Company since June of 2015. Mr. Kline was appointed to the Compensation Committee and Nominating and Corporate Governance Committee of the Board. The following is a summary of transactions by us since our previous disclosure on Form 10-K filed with the Securities and Exchange Commission on April 14, 2016 as amended by Form 10-K/A for the year ended December 31, 2015, as filed with the SEC on April 21, 2016 (together, the "Form 10-K") involving sales of our securities that were not registered under the Securities Act of 1933, as amended (the "Securities Act"). Each offer and sale was exempt from registration under either Section 4(2) of the Securities Act or Rule 506 under Regulation D of the Securities Act because (i) the securities were offered and sold only to accredited investors; (ii) there was no general solicitation or general advertising related to the offerings; (iii) each investor was given the opportunity to ask questions and receive answers concerning the terms of and conditions of the offering and to obtain additional information; (iv) the investors represented that they were acquiring the securities for their own account and for investment; and (v) the securities were issued with restrictive legends: On May 5, 2016, we granted an unrelated third party a warrant to acquire 7,500,000 shares of common stock in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 11, 2016, we granted a total of 3,100,000 shares of restricted stock to David Loftus, an affiliate of the Company, at a price of $0.02 per share in consideration of a reduction in debt. On May 11, 2016, we granted a total of 3,380,764 shares of restricted stock to Spanky LLC owned by David Loftus, an affiliate of the Company, at a price of $0.02 per in consideration of a reduction in debt. On May 12, 2016, The RHL Group, Inc., an entity affiliated with our Chairman & CEO Robert H. Lorsch, elected to purchase 5,000,000 shares of common stock at a price of $0.02 per share in consideration of partial waiver of principal amount under the Tenth Amended Note. On May 12, 2016, we granted Robert H. Lorsch, our Chairman & CEO, a warrant to acquire 10,000,000 shares of common stock in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Bernard Stolar, a Director and Acting Chief Financial Officer of the Company, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Bernard Stolar, a member of our Board of Directors and Acting Chief Financial Officer of the Company, a warrant to acquire 500,000 shares of common stock in consideration for services as Acting CFO. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Titus Day, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services in joining the Board on May 11, 2015. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Titus Day, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Mike Finley, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Scott Kline a warrant to acquire 500,000 shares of common stock in partial consideration of legal services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted Scott Kline, appointed to the Company's Board of Directors on May 12, 2016, a warrant to acquire 1,000,000 shares of common stock in consideration for services in joining the Board. The warrant has an exercise price of $0.02 per share and vests after December 31, 2016, with an expiration date of January 2, 2020. On May 12, 2016, we granted Dr. Ivor Royston, a member of our Board of Directors, a warrant to acquire 1,000,000 shares of common stock in consideration for services as a Director of the Company. The warrant has an exercise price of $0.02 per share, and vests after December 31, 2016, with an expiration date of January 2, 2020. On May 12, 2016, we granted four warrants to acquire a combined total of 2,250,000 shares of common stock to individual employees of the Company in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 300,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 200,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 200,000 shares of common stock to an unrelated third party in consideration for services. The warrant has an exercise price of $0.02 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. On May 12, 2016, we granted a warrant to acquire 10,000,000 shares of common stock to an unrelated third party in consideration of legal services. The warrant has an exercise price of $0.04 per share, with an expiration date of May 13, 2019, and is immediately vested at the date of grant. All securities granted or sold under these agreements are unregistered and may only be resold or transferred if they later become registered or fall under an exemption to the Securities Act or applicable state laws. Our typical investor or grantee generally relies upon Rule 144 of the Securities Act, which, in addition to requiring several other conditions before resale may occur, requires that the securities issued be held for a minimum of six months. We generally used the proceeds of the foregoing sales of securities for repayment of indebtedness, working capital and other general corporate purposes.